Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.45 |
| ▸ | CNR2 | P34972 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8082725 | 0.93 | ALDH1A1 (0.47) | ALDH1A1CYP3A4TSHRSMN1; SMN2TP53 | |
| SCHEMBL3526348 | 0.89 | ALDH1A1 (0.44) | ALDH1A1CYP3A4TSHRSMN1; SMN2TP53 | |
| SCHEMBL173301 | 0.86 | ALDH1A1 (0.64) | ALDH1A1CYP3A4TSHRSMN1; SMN2TP53 | |
| Phosphine SCHEMBL28908227 | 0.83 | ALDH1A1 (0.61) | ALDH1A1CYP3A4TSHRSMN1; SMN2TP53 | |
| Bromide SCHEMBL8645583 | 0.83 | ALDH1A1 (0.61) | ALDH1A1CYP3A4TSHRSMN1; SMN2TP53 | |
| Water SCHEMBL29179560 | 0.83 | ALDH1A1 (0.61) | ALDH1A1CYP3A4TSHRSMN1; SMN2TP53 | |
| Hydrogen Peroxide SCHEMBL7816450 | 0.80 | ALDH1A1 (0.58) | ALDH1A1CYP3A4TSHRSMN1; SMN2TP53 | |
| Hydrogen Peroxide SCHEMBL5496256 | 0.80 | ALDH1A1 (0.58) | ALDH1A1CYP3A4TSHRSMN1; SMN2TP53 | |
| SCHEMBL6554880 | 0.80 | ALDH1A1 (0.48) | ALDH1A1CYP3A4TSHRSMN1; SMN2TP53 | |
| SCHEMBL20391245 | 0.79 | ALDH1A1 (0.42) | ALDH1A1CYP3A4TSHRSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456701-B | Modulation of complement activity | RA制药公司 | 2020-01-07 | — | — | CN | claimed |
| CN-106456701-A | Modulation of complement activity | RA制药公司 | 2017-02-22 | — | — | CN | claimed |
| EP-0422040-A4 | HERBICIDAL BICYCLIC 1,3-DIKETONE DERIVATIVES | — | 1991-08-07 | — | — | EP | claimed |
| EP-0422040-A1 | HERBICIDAL BICYCLIC 1,3-DIKETONE DERIVATIVES | DUNLENA PTY. LIMITED (AU) | 1991-04-17 | — | — | EP | claimed |
| WO-1989012041-A1 | HERBICIDAL BICYCLIC 1,3-DIKETONE DERIVATIVES | DUNLENA PTY. LIMITED (AU) | 1989-12-14 | — | — | WO | claimed |
| JP-3141237-A | — | — | None | — | — | JP | disclosed |
| US-20240182526-A1 | COMPOSITIONS AND METHODS FOR MODULTING INFLAMMATORY AND DEGENERATIVE DISORDER | UNIV SOUTHERN CALIFORNIA (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240156896-A1 | Modulators of Complement Activity | UCB HOLDINGS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-11965040-B2 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240052109-A1 | POLYSILOXANE VINYLIC MONOMERS AND USES THEREOF | ALCON INC. (CH) | 2024-02-15 | — | — | US | disclosed |
| US-20240024520-A1 | AUTONOMOUS KNOB DOMAIN PEPTIDES | UCB Biopharma SRL (BE) | 2024-01-25 | — | — | US | disclosed |
| US-20230265235-A1 | CURABLE POLYFARNESENE-BASED COMPOSITIONS | FINA TECHNOLOGY, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| JP-H03141237-A | FLUORINE-CONTAINING TRICYCLIC COMPOUND HAVING OXYMETHYLENE BOND | DAINIPPON INK & CHEM INC | 1991-06-17 | — | — | JP | disclosed |
| EP-0431173-A1 | CURING AGENT, METHOD OF PREPARATION THEREOF, AND CURABLE COMPOSITION PREPARED THEREFROM | Kanegafuchi Chemical Industry Co., Ltd. (JP) | 1991-06-12 | — | — | EP | disclosed |
| US-5019576-A | Anticoagulants | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1991-05-28 | — | — | US | disclosed |
| EP-0415404-A2 | Process for producing unsaturated group-terminated high-molecular weight polyalkylene oxide | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-03-06 | — | — | EP | disclosed |
| EP-0312967-A1 | Sealant for double-layered glass | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-04-26 | — | — | EP | disclosed |
| US-4411912-A | Insecticidal isovaleric acid esters | ZOECON CORPORATION (US) | 1983-10-25 | — | — | US | disclosed |
| US-4243819-A | Substituted amino acids | ZOECON CORPORATION (US) | 1981-01-06 | — | — | US | disclosed |
| US-3971751-A | ROOM TEMPERATURE | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156896-A1 | Modulators of Complement Activity | C3AR1, C1QBP, C5AR1 | ALDH1A1 4679/4885CYP3A4 4400/4885TSHR 551/4885 |
| US-11965040-B2 | Modulation of complement activity | C5, C3AR1, CFH | ALDH1A1 3629/4885CYP3A4 3653/4885TSHR 1539/4885 |
| US-20240182526-A1 | COMPOSITIONS AND METHODS FOR MODULTING INFLAMMATORY AND DEGENERATIVE DISORDER | TNF, AGER, GRN | ALDH1A1 3176/4885CYP3A4 4869/4885TSHR 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.